Analytical Profile: Celltrion Healthcare Ireland Limited.
Key data on tenders won by this company, activity trends, and recent successes.
Tenders Won (12m)
4
Total Won Value (12m)
€12.1M
Average Contract Won
€3.0M
Top Category Won
Medical equipments, pharmaceuticals and personal care products
Celltrion Healthcare Ireland Limited. is a company actively participating in and winning public tenders. We present an analytical overview of their wins and contract values over the past 12 months.
According to our data, this company has won 4 tenders in the last year, with a total estimated value of €12.1M. The average contract value during this period was €3.0M, providing insight into the typical size of their successful bids.
Public Data vs. Professional Intelligence
You are viewing a free, public snapshot of this company's activity. The tend.ee Professional plan unlocks real-time data, predictive analytics, and our full AI-powered competitive analysis for this and thousands of other companies.
Recent Tenders (Sample)
| Date | Title | Status | Value (EUR) |
|---|---|---|---|
| 2025-10-23 | Ireland – Pharmaceutical products – DPS Tender for the Supply of Rituximab Solution for Infusion – CHI Hospital Group | Tender Result | €119K |
| 2025-10-23 | Ireland – Pharmaceutical products – DPS Tender for the Supply of Infliximab Intravenous Infusion HSE West and North West | Tender Result | €8.4M |
| 2025-09-25 | Ireland – Pharmaceutical products – HSE 25092 Supply of Infliximab Intravenous Infusion to Connolly Hospital Blanchardstown and Our Ladys Hospital Navan | Tender Result | €598K |
| 2025-09-18 | Ireland – Pharmaceutical products – Supply of Infliximab Intravenous Infusion to Children’s Health Ireland Hospital Group | Tender Result | €3.0M |
Analyze with tend.ee AI Co-pilot
Consult your personalized AI Co-pilot on your winning strategy.
Access all 4 tenders from this category.
Get real-time alerts for new opportunities.
Analyze historical winners and competitors.
No card required. Limited-time offer with basic personalization.